Previous 10 | Next 10 |
2023-11-08 16:12:13 ET More on Natera Natera: Cash Burn Remains A Concern Natera: Strong Growth Amidst Profitability Challenges Canaccord sees solid Q3 earnings for medtech; likes Quanterix, Natera, Guardant Natera prevails in patent battle as Supreme Court d...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2023. Recent Strategic and Financial Highlights Generated total revenues of $268.3 million in the third quarter of 2023, compared to $210...
Study to evaluate effectiveness of switching treatment to elacestrant in early breast cancer based on the detection of molecular relapse with Signatera ™ Approximately 1,900 early-stage breast cancer patients to be screened at 120+ sites in Europe Natera, Inc. (NASDAQ...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Natera Inc. (NTRA) is expected to report $-0.96 for Q3 2023
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the following investor conferences in November. A live webcast and audio archive of each event may be accessed through the investor relations section of the Natera website at ...
Study found 1 in 5 patients was positive for a genetic cause of CKD, 1 in 2 positive patients received a new or reclassified diagnosis, and 1 in 3 positive patients had a change in treatment plan Diagnostic yield and utility exceed clinical precedents for implementation of routine genetic...
2023-10-29 17:28:12 ET More on Guardant Health, Natera, etc. Natera: Cash Burn Remains A Concern Guardant Health: Peeling Back Economic Layers, Compressed Market Values Appear Justified Pacific Biosciences: Looks Appealing In The Fast-Growing Long-Read Sequencing Mar...
2023-10-25 14:17:58 ET Summary Today, we circle back on Natera, Inc., a fast-growing diagnostic testing concern. The company continues to rack up impressive sales growth, but its cash burn remains a primary concern. With Natera, Inc. stock down some 30% from recent highs, is n...
Builds on published evidence with twice as many patients and disease-free survival data extended to 24 months Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced updated data from the GALAXY arm of the CIRCULATE-Japan trial further showcasing the a...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 12:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-13 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...